scholarly journals H\(_{2}\)O\(_{2}\) production in Lactobacillus strains isolated from the intestinal microbiome of healthy people

2020 ◽  
Vol 42 (1) ◽  
Author(s):  
Ha Thi Thu ◽  
Hoang The Hung ◽  
Tran Xuan Thach ◽  
Nguyen Thi Hoa ◽  
La Thi Lan Anh ◽  
...  
Keyword(s):  
Ph Value ◽  
Survival Rates ◽  
Inhibition Zone ◽  
Healthy People ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
High Similarity ◽  
Stool Samples ◽  
Culture Supernatants ◽  
Lactobacillus Spp

Lactobacillus sp. in the digestive tract are capable of producing H2O2 to inhibit the growth of harmful bacteria and balance the gut microflora. In this study, we have isolated 115 strains of Lactobacillus spp. from stool samples of healthy people in Ha Noi. Of the 50 tested Lactobacillus strains, 9 strains were capable of producing H2O2, of which the Lac.VFE-14 strain produced highly H2O2 with a concentration of 2.183 mM, followed by Lac.VFE-08 strains (2.081 mM) and Lac.VFE-04 (2.067 mM). All three strains grew well in MRS medium supplemented with bile salts or adjusted to low pH value. With 0.3% of bile salt, the survival rates of these 3 strains were 99%, 95% and 97%, respectively. At pH 3.0, after 3 hours of cultivation, the survival rates of the three strains were 98.54%, 94.15% and 95.27%, respectively. In addition, each of the cell-free culture supernatants of these three strains that inhibit the growth of S. aureus ATCC-23235. The inhibition zone diameters of the three strains were 19.0±1.0 mm, 14.0±1.0 mm and 11.7±1.3 mm, respectively. The results of 16S rRNA gene analyses showed that Lac.VFE-14, Lac.VFE-08 and Lac.VFE-04 had high similarity scores with L. plantarum ZZU 23 (100%), L. rhamnosus JCM 1136 (99%) and L. plantarum S7 (98.65%), respectively. This study indicates that all three strains have the potential to be used as probiotics in the future.  

scholarly journals The Microbiota Diversity Following Antibiotic Treatment of Clostridium Difficile Infection

2020 ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Stool Samples

Abstract Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause diarrheal disease. A dominant risk factor is antibiotic treatment that disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to C. difficile infection (CDI) onset and patient gut microbiota.Methods: Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene using the Illumina MiSeq platform and QIIME2.Results: In total, 84 patients with C. difficile infection were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) had received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n=44 cases). The intestinal microbiota of the patients was not uniform. Differences in intestinal microbiome were influenced by the different combinations of antibiotics that the patients had received (p = 0.022)Conclusions: The number of different antibiotics administered has a major impact on the CDI patients gut microbiome, mainly on bacterial richness.

scholarly journals Microbiota diversity following antibiotic treatment of Clostridium difficile infection

2020 ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Stool Samples

Abstract Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause C. difficile infection (CDI), a diarrheal disease. A dominant risk factor is antibiotic treatment, which disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to CDI onset and patient gut microbiota during the infection.Methods: Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene, using the Illumina MiSeq platform and QIIME2.Results: In total, 84 patients with CDI were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n=44 cases). The intestinal microbiota of the patients was not uniform. Differences in intestinal microbiome were influenced by the different numbers of antibiotics families that the patients received (p = 0.022)Conclusions: The number of different antibiotics amount has a major impact on the gut microbiome of CDI patients, particularly on its bacterial richness.

scholarly journals Rapidly Processed Stool Swabs Approximate Stool Microbiota Profiles

mSphere ◽  
2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Nicholas A. Bokulich ◽  
Juan Maldonado ◽  
Dae-Wook Kang ◽  
Rosa Krajmalnik-Brown ◽  
J. Gregory Caporaso
Keyword(s):  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Sample Collection ◽  
Microbial Composition ◽  
Experimental Conditions ◽  
Fecal Matter ◽  
Bacterial Composition ◽  
Ambient Temperatures ◽  
Stool Samples ◽  
Stool Microbiota

ABSTRACTStudies of the intestinal microbiome commonly utilize stool samples to measure the microbial composition in the distal gut. However, collection of stool can be difficult from some subjects under certain experimental conditions. Sampling of fecal material using sterile swabs can streamline sample collection, handling, and processing. In this study, we validate the use of swabs of fecal matter to approximate measurements of microbiota in stool using 16S rRNA gene Illumina amplicon sequencing and evaluate the effects of shipping time at ambient temperatures on accuracy. The results indicate that swab samples reliably replicate the stool microbiota bacterial composition, alpha diversity, and beta diversity when swabs are processed quickly (≤2 days) but that sample quality quickly degrades after this period and is accompanied by increased abundances ofEnterobacteriaceae. Fresh swabs appear to be a viable alternative to stool sampling when standard collection methods are challenging, but extended exposure to ambient temperatures prior to processing threatens sample integrity.IMPORTANCECollection of fecal swab samples simplifies handling, processing, and archiving compared to collection of stool. This study confirms that fecal swabs reliably replicate the bacterial composition and diversity of stool samples, provided that the swabs are processed shortly after collection. These findings support the use of fecal swabs, when shipping and handling are done properly, to streamline measurements of intestinal microbiota.

scholarly journals The microbiota diversity following antibiotic treatment in Clostridium difficile infection

2020 ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Stool Samples

Abstract Background Clostridium difficile ( C. difficile ) is a major nosocomial pathogen that infect the human gut and can cause C. difficile infection (CDI), a diarrheal disease. A dominant risk factor is antibiotic treatment that disrupts the normal gut microbiota. The aim of the study is to examine the correlation between antibiotic treatment received prior to C. difficile infection (CDI) onset and patient gut microbiota Methods Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene using the Illumina MiSeq platform and QIIME2. Results In total, 84 patients with C. difficile infection were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n=44 cases). The intestinal microbiota of the patients was not uniform. Differences in intestinal microbiome were influenced by the different combinations of antibiotics that the patients received ( p = 0.022) Conclusions The number of different antibiotics combinations has a major impact on the CDI patients gut microbiome, mainly on bacterial richness.

scholarly journals The microbial diversity following antibiotic treatment of Clostridioides difficile infection

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dana Binyamin ◽  
Orna Nitzan ◽  
Maya Azrad ◽  
Zohar Hamo ◽  
Omry Koren ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Antibiotic Treatment ◽  
Gut Microbiome ◽  
Diarrheal Disease ◽  
Medical Center ◽  
Disease Onset ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Clostridioides Difficile ◽  
Stool Samples

Abstract Background Clostridioides difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause diarrheal disease. A dominant risk factor is antibiotic treatment that disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to C. difficile infection (CDI) onset and patient gut microbiota. Methods Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene using the Illumina MiSeq platform and QIIME2. Results In total, 84 patients with CDI were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) had received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n = 44 cases). The intestinal microbiota of the patients was not uniform and was mainly dominated by Proteobacteria. Differences in intestinal microbiome were influenced by the different combinations of antibiotics that the patients had received (p = 0.022) Conclusions The number of different antibiotics administered has a major impact on the CDI patients gut microbiome, mainly on bacterial richness.

scholarly journals Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Lito E. Papanicolas ◽  
Sarah K. Sims ◽  
Steven L. Taylor ◽  
Sophie J. Miller ◽  
Christos S. Karapetis ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Relative Abundance ◽  
Haematological Malignancy ◽  
Amplicon Sequencing ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Conventional Chemotherapy ◽  
Myelosuppressive Chemotherapy ◽  
Gram Positive Bacteria ◽  
Faecal Samples

Abstract Background The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects the gut microbiota in humans with non-haematological malignancy, independent of antibiotic exposure, is unknown. Methods Faecal samples from 19 participants with non-haematological malignancy, who were receiving conventional chemotherapy regimens but not antibiotics, were examined prior to chemotherapy, 7–12 days after chemotherapy, and at the end of the first cycle of treatment. Gut microbiota diversity and composition was determined by 16S rRNA gene amplicon sequencing. Results Compared to pre-chemotherapy samples, samples collected 7–12 days following chemotherapy exhibited increased richness (mean 120 observed species ± SD 38 vs 134 ± 40; p = 0.007) and diversity (Shannon diversity: mean 6.4 ± 0.43 vs 6.6 ± 0.41; p = 0.02). Composition was significantly altered, with a significant decrease in the relative abundance of gram-positive bacteria in the phylum Firmicutes (pre-chemotherapy median relative abundance [IQR] 0.78 [0.11] vs 0.75 [0.11]; p = 0.003), and an increase in the relative abundance of gram-negative bacteria (Bacteroidetes: median [IQR] 0.16 [0.13] vs 0.21 [0.13]; p = 0.01 and Proteobacteria: 0.015 [0.018] vs 0.03 [0.03]; p = 0.02). Differences in microbiota characteristics from baseline were no longer significant at the end of the chemotherapy cycle. Conclusions Conventional chemotherapy results in significant changes in gut microbiota characteristics during the period of predicted myelosuppression post-chemotherapy. Further study is indicated to link microbiome changes during chemotherapy to clinical outcomes.

scholarly journals Antibacterial activity of ginger extracts on bacteria isolated from digestive tract infection patients attended Muhoza Health Center

2020 ◽  
Vol 11 (2) ◽  
pp. 35-41
Author(s):  
Callixte Yadufashije ◽  
Adolyne Niyonkuru ◽  
Emanuel Munyeshyaka ◽  
Sibomana Madjidi ◽  
Joseph Mucumbitsi
Keyword(s):  
Antimicrobial Activity ◽  
Antibacterial Activity ◽  
Tract Infection ◽  
Health Center ◽  
Digestive Tract ◽  
Inhibition Zone ◽  
Ginger Extract ◽  
E Coli ◽  
Shigella Spp ◽  
Stool Samples

Background: Ginger (Zingiber officinale) has been used for long time due to its potential antimicrobial activity against diversity of microbial pathogens. Aims and Objectives: The study was carried out to investigate the bacteria pathogens found in digestive tract infections and assess antimicrobial activities of ginger extract to identified bacteria. Materials and Methods: Bacteriological studies were carried out on stool samples from 30 patients attending Muhoza health center. Different types of bacteria were isolated from stool samples of digestive tract infection patients by using various methods such culture, biochemical test and antimicrobial activity of ginger extracts was analyzed at INES-Ruhengeri in clinical microbiology laboratory. Results: Study findings showed isolated bacteria and antibacterial activity of Ginger. Isolated bacteria and their percentages including Escherichia coli (46.6%) which is the predominant isolated bacteria, Salmonella species (33.33%), Enterobacter spp (10.0%), Shigella spp (6.6%) and Citrobacter (3.33%) which is the least isolated bacteria. Antibacterial activity of ginger was seen on isolated bacteria, as ethanol and methanol were used for ginger oil extraction, the antibacterial activity of ginger extracts using ethanol was seen on isolated bacteria such us Citrobacter spp with 14 mm of inhibition zone, Shigella spp with 12 mm, Salmonella with 11.1 mm, E. coli with 9.5 mm and Enterobacter spp which was seen to be resistant to ginger extract using ethanol with 0.66mm of inhibition zone. For methanol extracts antibacterial activity was seen as follows: Citrobacter spp at 12 mm, Shigella spp at 11 mm, E. coli at 8 mm, salmonella spp at 6.1 mm, and Enterobacter spp with 5 mm. Enterobacter spp was seen to be the most resistant bacteria in both extracts. Conclusion: Ginger has shown to have an antibacterial activity on bacteria isolated from digestive tract infected patients. It can be used as a medicine to treat these infections. Number of researches should be done to be sure on this reality of antibacterial activity of ginger.

scholarly journals Description of Citrobacter cronae sp. nov., isolated from human rectal swabs and stool samples

2020 ◽  
Vol 70 (5) ◽  
pp. 2998-3003 ◽  
Author(s):  
Philipp Oberhettinger ◽  
Leonard Schüle ◽  
Matthias Marschal ◽  
Daniela Bezdan ◽  
Stephan Ossowski ◽  
...  
Keyword(s):  
New Species ◽  
University Hospital ◽  
Whole Genome Sequencing Data ◽  
Rrna Gene ◽  
Content Type ◽  
Link Type ◽  
Separate Branch ◽  
Rectal Swabs ◽  
Stool Samples ◽  
Type Strains

Nine independent Gram-negative bacterial strains were isolated from rectal swabs or stool samples of immunocompromised patients from two different wards of a university hospital. All isolates were phylogenetically analysed based on their 16S rRNA gene sequence, housekeeping gene recN, multilocus sequence analysis of concatenated partial fusA, leuS, pyrG and rpoB sequences, and by whole genome sequencing data. The analysed strains of the new species cluster together and form a separate branch with Citrobacter werkmanii NBRC105721T as the most closely related species. An average nucleotide identity value of 95.9–96% and computation of digital DNA–DNA hybridization values separate the new species from all other type strains of the genus Citrobacter . Biochemical characteristics further delimit the isolates from closely related Citrobacter type strains. As a result of the described data, a new Citrobacter species is introduced, for which the name Citrobacter cronae sp. nov. is proposed. The type strain is Tue2-1T with a G+C DNA content of 52.2 mol%.

scholarly journals The Effects of Chinese Medicine QRD, Antibiotics, and Probiotics on Therapy and Gut Microbiota in Septic Rats

2021 ◽  
Vol 11 ◽  
Author(s):  
Huiling Cao ◽  
Chunhui Zong ◽  
Wenkui Dai ◽  
Qiaoying Gao ◽  
Donghua Li ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Gut Microbiota ◽  
Survival Rates ◽  
Amplicon Sequencing ◽  
Medical Emergency ◽  
Control Group ◽  
Rrna Gene ◽  
Sham Operation ◽  
Therapeutic Effects

Sepsis is a common and often treacherous medical emergency with a high mortality and long-term complications in survivors. Though antibiotic therapy can reduce death rate of sepsis significantly, it impairs gut microbiota (GM), which play imperative roles in human health. In this study, we compared the therapeutic effects of antibiotics, probiotics, and Chinese medicine QRD on the survival rates of septic model and observed the GM characteristics of experimental rats via 16S rRNA gene amplicon sequencing. The 72 h survival rates of septic rat demonstrated the significant therapeutic effects in the three groups treated with antibiotics (AT), Chinses medicine QRD (QT), and probiotics (PT), which were elevated from the survival rate of 26.67% for the sepsis control group (ST) to 100.0% for AT, 88.24% for QT, and 58.33% for PT. The original characteristics of GM identified in the sham operation controls (SC) were relatively similar to those in PT and QT; nevertheless, the AT rats were shown dramatically decreased in the GM diversity. In addition, the septic rats in AT were revealed the higher abundances of Escherichia Shigella, Proteus, Morganella, Enterococcus, and Lysinibacillus, but the lower those of Parabacteroides, Alistipes, Desulfovibrio, Bacteroides, Helicobacter, Mucispirillum, Oscillibacter, Lachnospiraceae, and Ruminiclostridium 9, when compared to the PT and QT rats. By contrast, the GM of PT and QT rats shared similar diversity and structure. Our findings indicated that QRD increased the survival rates without impairment of the GM characteristics, which provides novel insights into the role of Chinese medicine in therapy and long-term recovery of sepsis.

scholarly journals Endophytic Bacteria from Faloak Plant Seed (Sterculia comosa Wallich) as Antibacterial Agent

2018 ◽  
Vol 10 (3) ◽  
pp. 546-552
Author(s):  
Maria Yasinta Moi ◽  
Endang Kusdiyantini ◽  
Sri Pujiyanto
Keyword(s):  
Antibacterial Agent ◽  
Endophytic Bacteria ◽  
Pathogenic Bacteria ◽  
Inhibition Zone ◽  
Biochemical Properties ◽  
Rrna Gene ◽  
Plant Seed ◽  
E Coli ◽  
Antibiotic Compounds ◽  
Screening Result

Endophytic bacteria isolated from some various kind of plants are able to yield some active compounds which have a role as an antibacterial compound. This work aimed to isolate and to screen the Endophytic bacteria from Faloak seed in its charge in inhibiting two kinds of pathogenic bacteria, Staphylococcus aureus and Escherichia coli. There were six isolates of Endophytic bacteria isolated in this work. According to the screening result, one isolate which had the most potential antibacterial activity (marked by the formation of inhibition zone) against S. aureus and E. coli. That most potential isolate was then tested and identified for both biochemical properties and molecular 16S rRNA gene. The result of this study showed that the endophytic bacteria isolate of Faloak seed with the code of S1 had the similarity with Enterobacter xiangfangensis strain 10-17 by 93 %. The research about endophytic bacteria of Faloak plants was never conducted before. Thus this research was expected to give information about the potential of antimicrobial ability Faloak plants which can be utilized in the discovery of new antibiotic compounds which in the future are expected to overcome the problem of microorganism resistance to antibiotics. The use of endophytic bacteria is expected to prevents the extinction of Faloak plants due to excessive use.

Sign in / Sign up

Export Citation Format

Share Document